Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) has announced plans to launch a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder (MDD) in the first half of 2027, with dosing expected to be completed by year-end. The Health Canada-authorized trial will enroll up to 200 participants across multiple Canadian sites and assess the safety and efficacy of a single supervised dose of Optimi's naturally derived psilocybin, manufactured at its Good Manufacturing Practice (GMP) facility.
The company will exclusively own the trial results and intends to provide periodic interim safety and efficacy readouts, with full topline results following completion of dosing and follow-up evaluations. Optimi stated that the study represents an initial step toward potential registration and can be funded with current cash on hand.
This development matters for several reasons. Major depressive disorder is a leading cause of disability worldwide, and existing treatments often fail to provide adequate relief for many patients. Psilocybin-assisted therapy has shown promise in early studies, and a large, controlled Phase 2 trial could generate robust data to support regulatory approval. For Canada, the trial reinforces the country's position as a leader in psychedelic research and pharmaceutical innovation. It also highlights the growing acceptance of psychedelic-assisted therapies within mainstream medicine.
Optimi Health is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. The company supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, visit https://www.optimi.net/.
The trial's outcomes could influence the broader pharmaceutical industry by demonstrating a scalable, regulatory-compliant pathway for psilocybin-based treatments. If successful, it may accelerate investment in psychedelic medicine and encourage other companies to pursue similar research. For patients, it offers hope for a new therapeutic option that addresses unmet needs in mental health care.
Optimi's ability to fund the trial with existing cash suggests financial stability and a strategic commitment to advancing its pipeline. The company's focus on natural psilocybin production also aligns with growing demand for plant-based and naturally derived pharmaceuticals. As the trial progresses, interim readouts will provide early signals of efficacy and safety, which could impact investor confidence and partnership opportunities.
NetworkNewsWire, a specialized communications platform, disseminated the announcement. The full press release is available at https://nnw.fm/ZLlie. For more information about NetworkNewsWire, visit https://www.NetworkNewsWire.com/.
